

# LOUISIANA BOARD OF PHARMACY

*Newsletter to Promote Pharmacy  
and Drug Law Compliance.*

## Upcoming Credential Renewals (26-04-827)

The renewal cycle for all certified pharmacy technician (CPT), automated medication system (AMS), and emergency drug kit (EDK) credentials is May 1 through June 30. Please check your email regularly during the last week of April for your renewal notice. Accounts that do not have an email address on file should expect to

receive a paper renewal notice by mail the first week of May. Any address change received after April 25, 2026, may not be reflected in the renewal mailing.

Any CPT, AMS, and EDK credentials not renewed by midnight on June 30, 2026, will expire.

## Use of AI in Pharmacy Practice (26-04-828)

Because artificial intelligence (AI) is a rapidly evolving field, the following reflects the Louisiana Board of Pharmacy's current position, as of February 25, 2026, and may be updated as developments occur.

The Board recognizes the use of AI as a tool to assist pharmacists in automating routine tasks, enhancing

efficiency, and improving patient safety. However, AI shall only be used as a support mechanism and not replace the pharmacist's professional judgment, clinical decision making, patient counseling, final verification, or responsibility for regulatory compliance and direct patient care.

*Access the National  
Pharmacy Compliance News*

*A Service of the National  
Association of Boards of Pharmacy  
Foundation® (NABPF®)*



## New Rules (26-04-829)

The Board completed the rulemaking process for three regulatory projects with publication of the rule changes in the March 20, 2026 edition of the *Louisiana Register*, with immediate effective dates. The Board distributed three separate email notices regarding the progress of these regulatory projects, in addition to maintaining the information on the [Regulatory Projects](#) page of the Board's website.

**Regulatory Project 2025-07 – Prescription Drug Delivery** amended Section 2501 of the Board's rules to address delivery of prescription drugs to patients. The rule changes add Section 2501(A)(4), requiring pharmacies to implement safeguards to protect medication integrity when delivering prescriptions to patients or their authorized agents. These changes address standards, notification, packaging, and temperature control for prescription drug delivery, as well as possession and control of the prescription drug, whether the pharmacy uses a common or contract carrier or a pharmacy employee. The rule changes also require pharmacies to replace any prescription drug that is compromised in any way during delivery.

**Regulatory Project 2025-08 – Centralized Prescription Dispensing** amended Section 1141 of the Board's rules relative to centralized prescription dispensing. The rule changes clarify the existing requirements related to prescription labeling and the maintenance of audit trail information. They further establish standards for the delivery of prepared prescriptions between a remote dispenser and an on-site pharmacy. Specifically,

the changes require that delivery be conducted in a manner that ensures the integrity of the medication by adhering to nationally recognized standards and address packaging and temperature control. The rule changes also address possession and control of prescription drugs during delivery, whether by a common carrier, contract carrier, or pharmacy employee, and prohibit the dispensing of any prescription drug compromised in transit. When prescriptions are not dispensed to patients, the rule changes require that they be returned to the remote dispenser pharmacy in situations where the remote dispenser and the on-site pharmacy operate under different ownership. Finally, the rule changes specify that the centralized prescription dispensing of controlled substances must comply with all applicable provisions of federal regulations set forth in 21 Code of Federal Regulations (CFR) Parts 1300 through 1399.

**Regulatory Project 2025-09 – Prescription Monitoring Program (PMP) Record Retention** amended Section 2914 of the Board's rules relative to PMP record retention. Pursuant to Act 159 of the 2025 Louisiana Legislature, which directs the Board to establish rulemaking standards for the retention, archiving, and destruction of PMP audit trail information, the rule amendment adds audit trail information to the records required to be maintained by the PMP. The amendment also simplifies existing regulatory language.

The Board's regulatory activity, which includes detailed information regarding each proposal and project, can be monitored on the Board's [Rulemaking Activity](#) section of its website.

## Spotlight on Compliance (26-04-830)

When a pharmacist receives a request to provide a service, it is important to evaluate whether that service is within the laws and regulations that govern pharmacy practice.

For instance, a prescriber may request that a pharmacist draw up doses of an injectable medication for a patient who has difficulty doing so for themselves. United States Pharmacopeia (USP) <797> defines

sterile compounding as "combining, admixing, diluting, pooling, reconstituting, repackaging, or otherwise altering a drug product or bulk drug substance to create a sterile preparation." Since drawing up doses of a sterile product is repackaging, that practice must meet the requirements of USP <797>, including environmental requirements, personnel training, and assigning beyond-use dates.

## Spotlight on Compliance (26-04-830)

(cont)

Board regulations addressing compounding, found in Chapter 25 Subchapter C, require compliance with USP <797> if compounding sterile preparations:

### **Louisiana Administrative Code 46:LIII.2535.A.2.**

All compounding shall be accomplished utilizing accepted pharmacy techniques, practices, and equipment, and in compliance with the Federal Food, Drug and Cosmetic Act of 1938 (FDCA) as subsequently amended, the current edition of Title 21 of the Code of Federal Regulations (CFR), and all relevant chapters of the United States Pharmacopeia-National Formulary.

a. The compounding of sterile preparations pursuant to the receipt of a patient-specific prescription shall comply with the provisions of section 503A of the FDCA and USP chapter 797.

Before agreeing to a request, research the topic and ensure an understanding of all applicable laws, regulations, and standards so that the actions of the pharmacist are compliant. Laws and regulations are available on the Board's website, [www.pharmacy.la.gov](http://www.pharmacy.la.gov), under the Resources tab. Remember that compliance with laws and regulations is the responsibility of each credential holder.

## Impersonation Scam (26-04-831)

The Board would like to warn all its credential holders of fraudsters impersonating Board staff and demanding sensitive information or payments. The impostors are not just identifying themselves as Board staff; they are also using Board phone numbers as caller ID. Scam tactics may include using an urgent

and aggressive tone, threatening arrest, referencing National Provider Identifier numbers and/or state license numbers, and more. Please keep in mind that the Board will not contact you by telephone and demand payment of funds for any reason.

## Disciplinary and Other Licensure Actions (26-04-832)

During its February 25, 2026 meeting, the Board acted in the following matters:

**Blanchard's Pharmacy, Inc, dba Blanchard's Pharmacy (New Roads, LA) (PHY.008031):** For allegedly dispensing misbranded drugs by using generic insulin products in place of certain brand-name insulins, the Board suspended the permit for five years beginning on February 25, 2026, and terminating on February 25, 2031, suspended the suspension, then placed the permit on probation for the period of suspension, subject to conditions; and further, assessed a fine of \$10,000 plus administrative and investigative costs.

**Trohn Peter Blanchard (PST.016704):** For his accountability as pharmacist-in-charge (PIC) of Blanchard's Pharmacy (PHY.008031) regarding the alleged dispensing of misbranded drugs by using

generic insulin products in place of certain brand-name insulins, the Board suspended his license for five years beginning on February 25, 2026, and terminating on February 25, 2031, suspended the suspension, then placed the license on probation for the period of suspension, subject to conditions; and further, assessed a fine of \$2,500 plus administrative costs.

### **Wellness Pharmacy, LLC (Baton Rouge, LA)**

**(PHY.008515):** For permitting an individual to assist in the practice of pharmacy prior to obtaining a credential, the Board issued a letter of reprimand; and further, assessed a fine of \$1,000 plus administrative and investigative costs.

**Olajide Brandon Bakare (PST.021337):** For his accountability as PIC of Wellness Pharmacy, LLC (PHY.008515) for permitting an individual to assist in the

## Disciplinary and Other Licensure Actions (26-04-832) (cont)

practice of pharmacy prior to obtaining a credential, the Board issued a letter of reprimand; and further, assessed administrative costs.

**Prelliana Marie Wilson (PTC.034292):** For assisting in the practice of pharmacy prior to obtaining a credential, the Board issued a letter of reprimand; and further, assessed a fine of \$250.

**Frank LaCorte (PST.018743):** For failing to report an order issued by the Florida Board of Pharmacy on March 27, 2025, on his Louisiana pharmacist license renewal application for the year 2026, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$1,000 plus administrative costs.

**Houry Lepedjian (PST.025064):** For failing to report an order issued by the Kansas State Board of Pharmacy on December 3, 2024, on her Louisiana pharmacist license renewal application for the year 2025, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$1,000 plus administrative costs.

**Iriel Balinda Crouch (CPT.015855):** For failing to report an adverse action as part of the pharmacy technician reinstatement application, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$250 plus administrative costs.

**Thinh Quoc Le (PST.022016):** For failing to report an adverse action as part of the pharmacist license renewal application for the year 2026, despite specific questioning for such information, the Board issued a letter of reprimand; and further, assessed a fine of \$1,000 plus administrative costs.

**Leslie Eileen Juneau (PST.016948):** The Board suspended her license for 10 years beginning on February 25, 2026, and terminating on February 25, 2036, suspended the suspension, then placed her credential on probation for the period of the suspension, subject to certain conditions enumerated within the voluntary consent agreement.

## Calendar Notes (26-04-833)

The next meeting of the Board and some of its committees is scheduled for May 5-6, 2026.

## Special Note (26-04-834)

The *Louisiana Board of Pharmacy Newsletter* is considered an official method of notification to pharmacies, pharmacists, pharmacy interns, pharmacy technicians, and pharmacy technician candidates credentialed by the Board. **These Newsletters will be used in administrative hearings as proof of notification.** Please read them carefully. Electronic copies dating back to 1998 are posted on the Board's website.

---

*The Louisiana Board of Pharmacy News is published by the Louisiana Board of Pharmacy and the National Association of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.*

M. Joseph Fontenot, Jr, RPh - State News Editor  
Lemrey "Al" Carter, PharmD, MS, RPh - National News Editor & Executive Editor  
Megan Pellegrini - Publications and Editorial Manager

---

3388 Brentwood Drive | Baton Rouge, LA 70809-1700 | [www.pharmacy.la.gov](http://www.pharmacy.la.gov)